ARCH Venture Partners
Venture Capital
Active
Chicago, United States
471
55M
245
12.39
55
0.48
87
- Stages of investment
- Areas of investment
Summary
In 1986 was created ARCH Venture Partners, which is appeared as VC. The leading representative office of defined VC is situated in the Chicago. The venture was found in North America in United States.
The fund was created by Clinton W. Bybee, Keith L. Crandell, Robert Nelsen, Steven Lazarus. We also calculated 6 valuable employees in our database.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the ARCH Venture Partners, startups are often financed by Lux Capital, In-Q-Tel, Alexandria Real Estate Equities. The meaningful sponsors for the fund in investment in the same round are Wellcome Trust, Third Rock Ventures, Sofinnova Investments. In the next rounds fund is usually obtained by Wellcome Trust, Versant Ventures, Lux Capital.
The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Software, Medical. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Juno Therapeutics, Receptos, GRAIL Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
The fund is constantly included in 7-12 investment rounds annually. The higher amount of exits for fund were in 2015. When the investment is from ARCH Venture Partners the average startup value is 50-100 millions dollars. This ARCH Venture Partners works on 7 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
- Check size
- 50K — 100M
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 2975000000
- Fund raised date
- 2022-06-29
Analytics
- Total investments
- 471
- Lead investments
- 55
- Exits
- 87
- Rounds per year
- 12.39
- Follow on index
- 0.48
- Investments by industry
- Biotechnology (327)
- Health Care (172)
- Therapeutics (116)
- Medical (105)
- Pharmaceutical (90) Show 139 more
- Investments by region
-
- United States (419)
- China (23)
- Ireland (3)
- United Kingdom (4)
- Switzerland (2) Show 5 more
- Peak activity year
- 2020
- Number of Unicorns
- 8
- Number of Decacorns
- 8
- Number of Minotaurs
- 8
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 140M
- Group Appearance index
- 0.97
- Avg. company exit year
- 9
- Avg. multiplicator
- 2.50
- Strategy success index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Elephas Biosciences | 30 Nov 2023 | Health Care, Medical Device, Medical | Late Stage Venture | 55M | United States, Wisconsin, Madison |
Moleculent | 11 Jun 2024 | Early Stage Venture | 26M | Stockholms Lan, Solna, Sweden |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.